Fosun Antengene raises RMB968M in capital increase, preps for HK listing

Key Takeaways:

Fosun Antengene raises RMB968 million from four investors
Parent Fosun Pharma contributes RMB550 million, stake dips to 68.47%
Proceeds fund R&D pipeline, production base expansion, and commercialization

Fosun Antengene, a controlling unit of Fosun Pharma (02196.HK), raised RMB968 million from four investors ahead of a planned Main Board listing on the Hong Kong Stock Exchange.

The capital increase represents approximately 12.15% of the total enlarged share capital. External investors will subscribe for a combined RMB418 million, while Fosun Pharma will contribute RMB550 million. The parent's stake in Fosun Antengene will decline to about 68.47% from roughly 70%, though the unit will remain a consolidated subsidiary.

Fosun Antengene is currently preparing for a Main Board listing on the Hong Kong Stock Exchange. As part of the process, option holders and the group entered into a Supplemental Agreement to the Letter of Undertaking, under which the relevant options were terminated as of yesterday. Should the listing plan be terminated, the options will automatically resume under the agreement.

Proceeds from the capital increase will be used for daily operations of Fosun Antengene and its controlling subsidiaries, including expanding its innovative R&D pipeline, strengthening core technologies, advancing production base construction to enhance industrialized supply capabilities, and increasing marketing and commercialization investment in products already launched.

The capital raise comes as Hong Kong's IPO market shows signs of a rebound, with Goldman Sachs recently highlighting a strong recovery in the city's new listing pipeline. The pricing implies Fosun Antengene will enter the Main Board with a strengthened balance sheet, though its final valuation will depend on market conditions at the time of listing. Investors will watch for the company's filing documents and indicative price range in the coming months.

This article is for informational purposes only and does not constitute investment advice.